Does the media refer more to LQDA or LBRX?

In the previous week, Liquidia had 9 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 15 mentions for Liquidia and 6 mentions for LB Pharmaceuticals. Liquidia's average media sentiment score of 0.75 beat LB Pharmaceuticals' score of 0.17 indicating that Liquidia is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 5 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LB Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, LBRX or DFTX?

LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LB Pharmaceuticals N/A N/A -$25.20M -$3.44 N/A Definium Therapeutics N/A N/A -$183.79M -$3.43 N/A

Is LBRX or DFTX more profitable?

LB Pharmaceuticals' return on equity of -25.92% beat Definium Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets LB Pharmaceuticals N/A -25.92% -24.68% Definium Therapeutics N/A -84.01% -63.66%

Does the media refer more to LBRX or DFTX?

In the previous week, LB Pharmaceuticals had 1 more articles in the media than Definium Therapeutics. MarketBeat recorded 6 mentions for LB Pharmaceuticals and 5 mentions for Definium Therapeutics. Definium Therapeutics' average media sentiment score of 0.82 beat LB Pharmaceuticals' score of 0.17 indicating that Definium Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LB Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Definium Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LBRX or AMRX?

In the previous week, LB Pharmaceuticals had 2 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 6 mentions for LB Pharmaceuticals and 4 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.85 beat LB Pharmaceuticals' score of 0.17 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LB Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Amneal Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LBRX or INDV?

In the previous week, Indivior had 2 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 8 mentions for Indivior and 6 mentions for LB Pharmaceuticals. Indivior's average media sentiment score of 1.15 beat LB Pharmaceuticals' score of 0.17 indicating that Indivior is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LB Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Indivior 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, MANE or LBRX?

Veradermics is trading at a lower price-to-earnings ratio than LB Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veradermics N/A N/A -$70M -$1.90 N/A LB Pharmaceuticals N/A N/A -$25.20M -$3.44 N/A

Is MANE or LBRX more profitable?

Veradermics' return on equity of 0.00% beat LB Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Veradermics N/A N/A N/A LB Pharmaceuticals N/A -25.92% -24.68%

Does the media refer more to MANE or LBRX?

In the previous week, LB Pharmaceuticals had 3 more articles in the media than Veradermics. MarketBeat recorded 6 mentions for LB Pharmaceuticals and 3 mentions for Veradermics. Veradermics' average media sentiment score of 0.58 beat LB Pharmaceuticals' score of 0.17 indicating that Veradermics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veradermics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LB Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

LB Pharmaceuticals (LBRX) Competitors

$47.52 -1.96 (-3.96%)

As of 09/3/2026 04:00 PM Eastern

Compare

LBRX vs. LQDA, DFTX, AMRX, INDV, and MANE

Should you buy LB Pharmaceuticals stock or one of its competitors? LB Pharmaceuticals's main competitors and comparable companies include Liquidia (LQDA), Definium Therapeutics (DFTX), Amneal Pharmaceuticals (AMRX), Indivior (INDV), and Veradermics (MANE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does LB Pharmaceuticals compare to Liquidia?

Liquidia (NASDAQ:LQDA) and LB Pharmaceuticals (NASDAQ:LBRX) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

Liquidia has a net margin of 30.74% compared to LB Pharmaceuticals' net margin of 0.00%. Liquidia's return on equity of 149.65% beat LB Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	30.74%	149.65%	36.30%
LB Pharmaceuticals	N/A	-25.92%	-24.68%

In the previous week, Liquidia had 9 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 15 mentions for Liquidia and 6 mentions for LB Pharmaceuticals. Liquidia's average media sentiment score of 0.75 beat LB Pharmaceuticals' score of 0.17 indicating that Liquidia is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	5 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LB Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Liquidia currently has a consensus target price of $98.08, indicating a potential upside of 42.92%. LB Pharmaceuticals has a consensus target price of $49.63, indicating a potential upside of 4.43%. Given Liquidia's higher possible upside, equities research analysts plainly believe Liquidia is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

LB Pharmaceuticals has lower revenue, but higher earnings than Liquidia. LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	38.80	-$68.92M	$1.37	50.09
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$3.44	N/A

64.5% of Liquidia shares are owned by institutional investors. 25.6% of Liquidia shares are owned by insiders. Comparatively, 5.8% of LB Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Liquidia beats LB Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

How does LB Pharmaceuticals compare to Definium Therapeutics?

LB Pharmaceuticals (NASDAQ:LBRX) and Definium Therapeutics (NASDAQ:DFTX) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

In the previous week, LB Pharmaceuticals had 1 more articles in the media than Definium Therapeutics. MarketBeat recorded 6 mentions for LB Pharmaceuticals and 5 mentions for Definium Therapeutics. Definium Therapeutics' average media sentiment score of 0.82 beat LB Pharmaceuticals' score of 0.17 indicating that Definium Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LB Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Definium Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LB Pharmaceuticals' return on equity of -25.92% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LB Pharmaceuticals	N/A	-25.92%	-24.68%
Definium Therapeutics	N/A	-84.01%	-63.66%

27.9% of Definium Therapeutics shares are owned by institutional investors. 5.8% of LB Pharmaceuticals shares are owned by company insiders. Comparatively, 2.4% of Definium Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$3.44	N/A
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A

LB Pharmaceuticals presently has a consensus target price of $49.63, suggesting a potential upside of 4.43%. Definium Therapeutics has a consensus target price of $63.00, suggesting a potential upside of 65.79%. Given Definium Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Definium Therapeutics is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Definium Therapeutics beats LB Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does LB Pharmaceuticals compare to Amneal Pharmaceuticals?

LB Pharmaceuticals (NASDAQ:LBRX) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

In the previous week, LB Pharmaceuticals had 2 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 6 mentions for LB Pharmaceuticals and 4 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.85 beat LB Pharmaceuticals' score of 0.17 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LB Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amneal Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amneal Pharmaceuticals has a net margin of 5.05% compared to LB Pharmaceuticals' net margin of 0.00%. LB Pharmaceuticals' return on equity of -25.92% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LB Pharmaceuticals	N/A	-25.92%	-24.68%
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

Amneal Pharmaceuticals has higher revenue and earnings than LB Pharmaceuticals. LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$3.44	N/A
Amneal Pharmaceuticals	$3.02B	1.89	$72.06M	$0.49	36.47

LB Pharmaceuticals currently has a consensus target price of $49.63, indicating a potential upside of 4.43%. Amneal Pharmaceuticals has a consensus target price of $19.00, indicating a potential upside of 6.32%. Given Amneal Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Amneal Pharmaceuticals is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Amneal Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.13

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 5.8% of LB Pharmaceuticals shares are owned by company insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Amneal Pharmaceuticals beats LB Pharmaceuticals on 11 of the 13 factors compared between the two stocks.

How does LB Pharmaceuticals compare to Indivior?

LB Pharmaceuticals (NASDAQ:LBRX) and Indivior (NASDAQ:INDV) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

Indivior has a net margin of 26.65% compared to LB Pharmaceuticals' net margin of 0.00%. LB Pharmaceuticals' return on equity of -25.92% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LB Pharmaceuticals	N/A	-25.92%	-24.68%
Indivior	26.65%	-283.11%	36.85%

60.3% of Indivior shares are held by institutional investors. 5.8% of LB Pharmaceuticals shares are held by company insiders. Comparatively, 0.7% of Indivior shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Indivior has higher revenue and earnings than LB Pharmaceuticals. LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$3.44	N/A
Indivior	$1.24B	3.32	$210M	$2.79	12.48

LB Pharmaceuticals presently has a consensus target price of $49.63, suggesting a potential upside of 4.43%. Indivior has a consensus target price of $45.17, suggesting a potential upside of 29.68%. Given Indivior's higher possible upside, analysts clearly believe Indivior is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Indivior	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Indivior had 2 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 8 mentions for Indivior and 6 mentions for LB Pharmaceuticals. Indivior's average media sentiment score of 1.15 beat LB Pharmaceuticals' score of 0.17 indicating that Indivior is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LB Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Indivior	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Indivior beats LB Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does LB Pharmaceuticals compare to Veradermics?

Veradermics (NYSE:MANE) and LB Pharmaceuticals (NASDAQ:LBRX) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

In the previous week, LB Pharmaceuticals had 3 more articles in the media than Veradermics. MarketBeat recorded 6 mentions for LB Pharmaceuticals and 3 mentions for Veradermics. Veradermics' average media sentiment score of 0.58 beat LB Pharmaceuticals' score of 0.17 indicating that Veradermics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veradermics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LB Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Veradermics currently has a consensus target price of $153.00, suggesting a potential upside of 56.60%. LB Pharmaceuticals has a consensus target price of $49.63, suggesting a potential upside of 4.43%. Given Veradermics' higher possible upside, equities analysts plainly believe Veradermics is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Veradermics is trading at a lower price-to-earnings ratio than LB Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	-$70M	-$1.90	N/A
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$3.44	N/A

Veradermics' return on equity of 0.00% beat LB Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
LB Pharmaceuticals	N/A	-25.92%	-24.68%

Summary

Veradermics and LB Pharmaceuticals tied by winning 5 of the 10 factors compared between the two stocks.

Get LB Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LBRX vs. The Competition

Export

Metric	LB Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.60B	$12.24B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	-13.81	787.27	273.28	25.38
Price / Sales	N/A	753.79	613.48	92.60
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	4.61	12.33	12.89	6.14
Net Income	-$25.20M	$2.82B	$3.47B	$349.01M
7 Day Performance	-0.44%	2.60%	0.61%	-0.27%
1 Month Performance	5.60%	6.96%	5.73%	0.68%
1 Year Performance	N/A	9.48%	25.37%	14.84%

LB Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LBRX LB Pharmaceuticals	1.2254 of 5 stars	$47.52 -4.0%	$49.63 +4.4%	N/A	$1.60B	N/A	N/A	16	News Coverage
LQDA Liquidia	4.2764 of 5 stars	$70.27 +2.4%	$98.08 +39.6%	+134.9%	$6.14B	$158.32M	51.29	50	Trending News
DFTX Definium Therapeutics	3.8579 of 5 stars	$43.27 -3.7%	$63.00 +45.6%	+319.4%	$6.03B	N/A	N/A	40
AMRX Amneal Pharmaceuticals	3.1673 of 5 stars	$17.78 -0.7%	$17.67 -0.6%	+87.3%	$5.72B	$3.02B	36.29	8,500
INDV Indivior	4.2343 of 5 stars	$36.18 -1.9%	$45.17 +24.8%	+41.2%	$4.35B	$1.33B	12.97	1,051	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LBRX) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LB Pharmaceuticals (LBRX) Competitors

LBRX vs. LQDA, DFTX, AMRX, INDV, and MANE

How does LB Pharmaceuticals compare to Liquidia?

Summary

How does LB Pharmaceuticals compare to Definium Therapeutics?

Summary

How does LB Pharmaceuticals compare to Amneal Pharmaceuticals?

Summary

How does LB Pharmaceuticals compare to Indivior?

Summary

How does LB Pharmaceuticals compare to Veradermics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LBRX vs. The Competition

LB Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LB Pharmaceuticals (LBRX) Competitors

LBRX vs. LQDA, DFTX, AMRX, INDV, and MANE

How does LB Pharmaceuticals compare to Liquidia?

Is LQDA or LBRX more profitable?

Does the media refer more to LQDA or LBRX?

Do analysts recommend LQDA or LBRX?

Which has preferable valuation & earnings, LQDA or LBRX?

Do insiders & institutionals have more ownership in LQDA or LBRX?

Summary

How does LB Pharmaceuticals compare to Definium Therapeutics?

Does the media refer more to LBRX or DFTX?

Is LBRX or DFTX more profitable?

Do institutionals & insiders hold more shares of LBRX or DFTX?

Which has preferable earnings & valuation, LBRX or DFTX?

Do analysts recommend LBRX or DFTX?

Summary

How does LB Pharmaceuticals compare to Amneal Pharmaceuticals?

Does the media prefer LBRX or AMRX?

Is LBRX or AMRX more profitable?

Which has higher valuation & earnings, LBRX or AMRX?

Do analysts rate LBRX or AMRX?

Do insiders & institutionals believe in LBRX or AMRX?

Summary

How does LB Pharmaceuticals compare to Indivior?

Is LBRX or INDV more profitable?

Do insiders and institutionals have more ownership in LBRX or INDV?

Which has stronger earnings & valuation, LBRX or INDV?

Do analysts rate LBRX or INDV?

Does the media prefer LBRX or INDV?

Summary

How does LB Pharmaceuticals compare to Veradermics?

Does the media refer more to MANE or LBRX?

Do analysts rate MANE or LBRX?

Which has stronger valuation and earnings, MANE or LBRX?

Is MANE or LBRX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LBRX vs. The Competition

LB Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools